JP2013515497A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515497A5
JP2013515497A5 JP2012546556A JP2012546556A JP2013515497A5 JP 2013515497 A5 JP2013515497 A5 JP 2013515497A5 JP 2012546556 A JP2012546556 A JP 2012546556A JP 2012546556 A JP2012546556 A JP 2012546556A JP 2013515497 A5 JP2013515497 A5 JP 2013515497A5
Authority
JP
Japan
Prior art keywords
cells
population
nicotinamide
cultured
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546556A
Other languages
English (en)
Japanese (ja)
Other versions
JP5943843B2 (ja
JP2013515497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2010/001091 external-priority patent/WO2011080740A1/en
Publication of JP2013515497A publication Critical patent/JP2013515497A/ja
Publication of JP2013515497A5 publication Critical patent/JP2013515497A5/ja
Application granted granted Critical
Publication of JP5943843B2 publication Critical patent/JP5943843B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546556A 2009-12-29 2010-12-29 ナチュラルキラー細胞の増殖および活性の強化方法 Expired - Fee Related JP5943843B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28219609P 2009-12-29 2009-12-29
US61/282,196 2009-12-29
PCT/IL2010/001091 WO2011080740A1 (en) 2009-12-29 2010-12-29 Methods for enhancing natural killer cell proliferation and activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016102993A Division JP6215394B2 (ja) 2009-12-29 2016-05-24 エクスビボ培養されたナチュラルキラー細胞の集団

Publications (3)

Publication Number Publication Date
JP2013515497A JP2013515497A (ja) 2013-05-09
JP2013515497A5 true JP2013515497A5 (cg-RX-API-DMAC7.html) 2014-02-13
JP5943843B2 JP5943843B2 (ja) 2016-07-05

Family

ID=43797654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546556A Expired - Fee Related JP5943843B2 (ja) 2009-12-29 2010-12-29 ナチュラルキラー細胞の増殖および活性の強化方法
JP2016102993A Expired - Fee Related JP6215394B2 (ja) 2009-12-29 2016-05-24 エクスビボ培養されたナチュラルキラー細胞の集団

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016102993A Expired - Fee Related JP6215394B2 (ja) 2009-12-29 2016-05-24 エクスビボ培養されたナチュラルキラー細胞の集団

Country Status (11)

Country Link
US (2) US20130011376A1 (cg-RX-API-DMAC7.html)
EP (3) EP3785712A1 (cg-RX-API-DMAC7.html)
JP (2) JP5943843B2 (cg-RX-API-DMAC7.html)
CN (2) CN102781449A (cg-RX-API-DMAC7.html)
AU (1) AU2010337829B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012016203A2 (cg-RX-API-DMAC7.html)
CA (1) CA2785627C (cg-RX-API-DMAC7.html)
DK (1) DK3184109T3 (cg-RX-API-DMAC7.html)
ES (2) ES2851601T3 (cg-RX-API-DMAC7.html)
IL (1) IL259642B (cg-RX-API-DMAC7.html)
WO (1) WO2011080740A1 (cg-RX-API-DMAC7.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP5016732B1 (ja) * 2011-03-02 2012-09-05 株式会社セレックス 癌発症抑制剤、抗体産生能増強剤及び肝炎治療剤
EP2686421B1 (en) 2011-03-18 2020-12-23 Glycostem Therapeutics B.V. Generation of nk cells and nk-cell progenitors
US9067997B2 (en) * 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Nk細胞の増幅方法
CN104204194B (zh) * 2011-12-22 2018-08-03 财团法人牧岩生命工学研究所 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (ja) * 2012-08-02 2016-02-09 阿部 博幸 単球またはnk細胞を入手する方法
EP3622960A1 (en) * 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Nk細胞の調製方法
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN105219710B (zh) * 2014-06-05 2020-01-10 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
RU2708199C2 (ru) * 2014-06-10 2019-12-04 Полибайосепт Аб Культуральная среда для клеточной иммунотерапии
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
US12398371B2 (en) 2015-01-27 2025-08-26 Korea Research Institute Of Bioscience Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
CN104673750B (zh) * 2015-02-13 2018-04-27 杭州易文赛生物技术有限公司 一种自然杀伤细胞扩增的方法和一种培养基组合物
WO2016172372A1 (en) 2015-04-23 2016-10-27 Baylor College Of Medicine Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same
US11040094B2 (en) * 2015-07-01 2021-06-22 Colleen M. O'Connor Compositions and methods for treating immunological dysfunction
US10288963B2 (en) * 2015-09-21 2019-05-14 Apple Inc. Display having gate lines with zigzag extensions
KR20180086204A (ko) * 2015-11-05 2018-07-30 글리코스템 떼라퓨틱스 비.브이. 면역치료법에 사용하기 위한 조성물
KR20170084951A (ko) * 2016-01-13 2017-07-21 삼성전자주식회사 광 편향기 및 디스플레이 장치
US11053293B2 (en) * 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
CN107267454B (zh) * 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
JP6763729B2 (ja) 2016-09-26 2020-09-30 矢崎総業株式会社 電池状態検出装置
GB201703476D0 (en) 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
EP3596201A4 (en) * 2017-03-15 2020-12-09 Immune Ventures, LLC IN VIVO PRIMING OF NATURAL KILLER CELLS
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
GB201704953D0 (en) * 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
EP3691660A4 (en) * 2017-10-02 2021-07-07 Gamida-Cell Ltd. EXPANSION AND USE OF EXPANDED NK CELL FRACTIONS
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
GB201807050D0 (en) * 2018-04-30 2018-06-13 Cellprotect Nordic Pharmaceuticals Ab Medical uses
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
US20200063104A1 (en) * 2018-08-22 2020-02-27 Wisconsin Alumni Research Foundation Expansion of hpsc-derived granulocytic and lymphoid progenitors with um171
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN109468361B (zh) * 2018-11-29 2021-11-02 电子科技大学 鱼类自然杀伤细胞杀伤细菌感染的单核/巨噬细胞能力的测定方法
CN109666639B (zh) * 2018-12-24 2021-03-26 浙江大学 一种杀伤活性增强的nk细胞及其制备方法
WO2020152661A1 (ja) * 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
EP3927353A4 (en) * 2019-02-24 2022-11-23 Gamida-Cell Ltd. METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用
CN109846866A (zh) * 2019-03-27 2019-06-07 中国科学院昆明植物研究所 对映-贝壳杉烷型二萜类化合物Parvifoline AA在制药中的应用
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP3962604A4 (en) * 2019-04-30 2023-02-08 Xcell Biosciences Inc. SYSTEMS AND METHODS FOR MODULATION OF A CELL PHENOTYPE
CA3143198A1 (en) * 2019-06-14 2020-12-17 G Tech Bio Llc Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
IL295964A (en) 2020-02-28 2022-10-01 Takeda Pharmaceuticals Co A method for producing natural killer cells from pluripotent stem cells
US12486492B2 (en) 2020-03-05 2025-12-02 Korea Research Institute Of Bioscience Method for producing memory-like NK cells with ability to express higher levels of NCRs, cytotoxicity, and IFN-γ than NK cells in human peripheral blood
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN111394310A (zh) * 2020-03-24 2020-07-10 北京荟科柘生物科技有限公司 一种强免疫调节,强杀伤肿瘤细胞和病毒感染细胞的增强nk细胞和其制备方法与试剂盒
CN111500535B (zh) * 2020-04-30 2023-04-14 惠和生物技术(上海)有限公司 用于体外培养人自然杀伤细胞的方法和培养基
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
JP2023546534A (ja) * 2020-10-12 2023-11-02 ライフ・テクノロジーズ・アクシェセルスカプ 生体細胞と共に使用するための磁性粒子処理システム及び関連する方法
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4232567A1 (en) 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
JP2021035400A (ja) * 2020-12-07 2021-03-04 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN113151169A (zh) * 2021-05-14 2021-07-23 上海赛笠生物科技有限公司 一种基于磁珠阳选策略分离自然杀伤细胞的方法
WO2022245813A2 (en) * 2021-05-18 2022-11-24 Verdure Biotech, Inc. A method for controlling viral infections through adoptive transfer of a cell product comprising an expanded and enriched population of superctivated cytokine killer cells
IL310226A (en) 2021-07-18 2024-03-01 Gamida Cell Ltd Therapeutic nk cell populations
CN118369418A (zh) 2021-08-10 2024-07-19 盖米达细胞有限公司 工程nk细胞、它们的生产方法及其用途
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
EP4426350A4 (en) * 2021-11-04 2025-09-24 Artiva Biotherapeutics Inc Treatment of cancer with nk cells and multispecific engagers
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
US20250017964A1 (en) * 2021-11-15 2025-01-16 City Of Hope Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
CN115887493A (zh) * 2022-07-04 2023-04-04 北京大学人民医院 Nk细胞的应用、nk细胞回输制剂以及组合制剂
CN115844926A (zh) * 2022-07-29 2023-03-28 深圳市汉科生物工程有限公司 去乙酰化酶抑制剂与nk细胞在制备激活并清除潜伏性hiv病毒药物方面的应用
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
CN116218781B (zh) * 2022-12-30 2025-08-01 四川阿思科力生物科技有限公司 Robo1 car-nk92细胞复苏培养基,试剂盒及复苏培养方法
CN116254233B (zh) * 2022-12-30 2025-08-05 四川阿思科力生物科技有限公司 一种robo1 car nk细胞的复苏及培养方法
CN118667760A (zh) * 2023-03-17 2024-09-20 深圳市三启生物技术有限公司 诱导多能干细胞分化为cd34+造血干/祖细胞的培养基组合
CN117660332A (zh) * 2023-11-07 2024-03-08 广东唯泰生物科技有限公司 一种nk细胞的体外培养方法
CN118903175B (zh) * 2024-07-25 2025-09-16 中国科学技术大学 小分子药物联用在增强低氧条件下nk细胞的代谢、杀伤能力中的应用
WO2026156062A2 (en) 2025-01-15 2026-07-23 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting cluster of differentiation 19 (cd19) and cluster of differentiation 22 (cd22)
WO2026165423A2 (en) 2025-01-31 2026-08-06 St. Jude Children's Research Hospital, Inc. Methods for enhancing immune effector cell activity leveraging biophysical modulation in adoptive cellular therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6231852B1 (en) * 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
AU1908395A (en) 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses
US6849452B1 (en) 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
US20060205071A1 (en) 2003-07-17 2006-09-14 Gamida-Cell Ltd. Methods for ex-vivo expanding stem/progenitor cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CN100359004C (zh) * 2003-12-19 2008-01-02 龚小迪 转基因表达细胞趋化因子的自然杀伤细胞
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
ES2409128T3 (es) * 2005-11-29 2013-06-25 Gamida Cell Ltd. Procedimientos de mejora de anidamiento e injerto de células madre
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
WO2007103901A2 (en) * 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
WO2008056368A2 (en) * 2006-11-09 2008-05-15 Gamida-Cell Ltd. Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
US20090234699A1 (en) 2008-03-15 2009-09-17 Microsoft Corporation User Interface For Scheduling Resource Assignments
CN101481678B (zh) * 2009-02-16 2011-04-06 中国科学技术大学 一种自然杀伤细胞及其培养方法

Similar Documents

Publication Publication Date Title
Kumar et al. HSC niche biology and HSC expansion ex vivo
US10792309B2 (en) Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
RU2756561C2 (ru) Среда для формирования колоний и её применение
US8685728B2 (en) Kit containing stem cells and cytokines for use in attenuating immune responses
Zhou et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells
AU2014344795B2 (en) Cell culture method
Mohty et al. In and out of the niche: perspectives in mobilization of hematopoietic stem cells
CN107254439A (zh) 增强自然杀伤细胞增殖和活性的方法
US20210355445A1 (en) Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same
JP6513729B2 (ja) 同種異系移植片
CN104789527A (zh) 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品
Huang et al. Systemic administration of allogeneic mesenchymal stem cells does not halt osteoporotic bone loss in ovariectomized rats
Monteiro et al. Association of mesenchymal stem cells with platelet rich plasma on the repair of critical calvarial defects in mice
Kumar Bone defect repair in mice by mesenchymal stem cells
Chen et al. Expanded donor natural killer cell and IL‐2, IL‐15 treatment efficacy in allogeneic hematopoietic stem cell transplantation
EP2442837B1 (en) Bone marrow extracellular matrix extract and therapeutic use thereof
CN113710257A (zh) γδT细胞归巢和保留的方法,可选地使用自然杀伤细胞,以用于生成用于治疗的细胞组合物
CN114222814A (zh) 具有比人外周血的自然杀伤细胞更高水平的自然细胞毒性受体、杀伤活性及γ-干扰素生产能力的记忆样自然杀伤细胞的制备方法
US9668463B2 (en) Mouse model for engraftment potential
Beksac et al. Modalities to improve cord blood engraftment
Moadsiri et al. Mesenchymal stem cells enhance xenochimerism in NK-depleted hosts
US20230383257A1 (en) Production of megakaryocytes and platelets in a co-culture system
Hosgood et al. Current basic research in normothermic machine perfusion
Negrin Role of regulatory T cell populations in controlling graft vs host disease
Pi et al. Next-Generation Cord Blood Expansion: Bridging the Cell Dose Gap with Bioengineered Niches and Clinical Breakthroughs